This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reich, T. Articles by Strandness, D. E. Search for Related Content PubMed PubMed Citation Articles by Reich, T. Articles by Strandness, D. E. Social Bookmarking                         What's this?

Pentoxifylline in the Treatment of Intermittent Claudication of the Lower Limbs

Bruce C. Cutler

Bok Y. Lee

John M. Porter

Frederick A. Reichle

John T. Scogin

D. Eugene Strandness

Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily, increased stepwise to 1200 mg daily at the end of one month) and 40 who took placebo for 24 weeks. Twenty-five patients on pentoxifylline and 21 on placebo were dropped from the study for reasons unrelated to the drug. Walking ability on a treadmill was increased significantly after 2 weeks and remained so throughout the study in the pentoxifylline vs. the placebo group. Ability to walk until first experiencing intermittent claudication was a more sensitive index than the maximum ability to walk. The drug did not cause changes in blood pressure or in heart rate. Other than mild nausea, there were no significant side effects.

Angiology, Vol. 35, No. 7, 389-395 (1984)
DOI: 10.1177/000331978403500701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Castano, R. Mas, R. Gamez, L. Fernandez, and J. Illnait Effects of Policosanol and Ticlopidine in Patients with Intermittent Claudication: A Double-Blinded Pilot Comparative Study Angiology, July 1, 2004; 55(4): 361 - 371. [Abstract] [PDF]

				G. Castano, R. Mas, L. Fernandez, R. Gamez, and J. Illnait Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study Angiology, January 1, 2003; 54(1): 25 - 38. [Abstract] [PDF]

				G. Castano, R. M. Ferreiro, L. Fernandez, R. Gamez, J. Illnait, and J. C. Fernandez A Long-Term Study of Policosanol in the Treatment of Intermittent Claudication Angiology, February 1, 2001; 52(2): 115 - 125. [Abstract] [PDF]

				G. Castano, R. Mas, J. Roca, L. Fernandez, J. Illnait, J. C. Fernandez, E. Selman, and R. Mas A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication Angiology, February 1, 1999; 50(2): 123 - 130. [Abstract] [PDF]

				D. J. Effeney, J. A. Stokes, and H. M. Trenerry The Trials and Tribulations of Pentoxifylline Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 123 - 137. [PDF]

				T. Reich and D. Gillings Effects of Pentoxifylline on Severe Intermittent Claudication Angiology, September 1, 1987; 38(9): 651 - 656. [Abstract] [PDF]

				R. Lee Kirby and R. W. Marlow Reliability of Walking Endurance with an Incremental Treadmill Test Angiology, July 1, 1987; 38(7): 524 - 529. [Abstract] [PDF]